Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.33 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22552061 | 0.89 | LIPG (0.38) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL22558742 | 0.87 | LPL (0.43) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL22655324 | 0.86 | LPL (0.38) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL22655326 | 0.86 | LPL (0.41) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL19951554 | 0.84 | FFAR1 (0.41) | LPLLIPGAAK1FFAR1BMPR1B | |
| SCHEMBL506778 | 0.83 | LPL (0.46) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL16465393 | 0.81 | LIPG (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL24094491 | 0.80 | LPL (0.39) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL22655354 | 0.79 | CA1 (0.42) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL506042 | 0.79 | LIPG (0.40) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2025-02-27 | — | — | US | disclosed |
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | PROTHENA BIOSCIENCES INC | 2025-02-27 | — | — | US | disclosed |
| EP-4444421-A2 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| EP-4444420-A2 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107723-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107723-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107714-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| WO-2022078403-A1 | SUBSTITUTED PYRIDONE COMPOUND AND APPLICATION | 江苏先声药业有限公司 | 2022-04-21 | — | — | WO | disclosed |
| EP-3713927-B1 | PYRIDINONE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | NOVARTIS AG (CH) | 2021-12-15 | — | — | EP | disclosed |
| US-11160797-B2 | Pyridinone derivatives and their use as selective ALK-2 inhibitors | NOVARTIS AG (CH) | 2021-11-02 | — | — | US | disclosed |
| US-9475802-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-10-25 | — | — | US | disclosed |
| US-20150274718-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | LABORATOIRE BIODIM (FR) | 2015-10-01 | — | — | US | disclosed |
| US-20150274718-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | LABORATOIRE BIODIM (FR) | 2015-10-01 | — | — | US | disclosed |
| US-20150274718-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | LABORATOIRE BIODIM (FR) | 2015-10-01 | — | — | US | disclosed |
| EP-2906539-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014057103-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014057103-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-04-17 | — | — | WO | disclosed |
| EP-2569313-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20120027874-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2011143426-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | DYRK1A, DYRK2, DYRK1B | LPL 4260/4885LIPG 3685/4885CA1 3329/4885 |
| US-20120027874-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | LPL 4640/4885LIPG 3962/4885CA1 4196/4885 |
| US-20150274718-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | RPL35, EIF2AK2, MAVS | LPL 3506/4885LIPG 1728/4885CA1 4880/4885 |
| US-11160797-B2 | Pyridinone derivatives and their use as selective ALK-2 inhibitors | ALK, ACVR2B, ACVR1B | LPL 2799/4885LIPG 2497/4885CA1 4749/4885 |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, PYGB | LPL 4583/4885LIPG 3800/4885CA1 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.